Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...
For reference, our fourth quarter and year-end 2025 earnings release, shareholder letter, and presentation are available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results